ErbB receptors: new insights on mechanisms and biology.

[1]  G. Corfas,et al.  Presenilin-Dependent ErbB4 Nuclear Signaling Regulates the Timing of Astrogenesis in the Developing Brain , 2006, Cell.

[2]  G. Carpenter,et al.  ErbB-4 s80 Intracellular Domain Abrogates ETO2-dependent Transcriptional Repression* , 2006, Journal of Biological Chemistry.

[3]  E. Petricoin,et al.  Dynamic Profiling of the Post-translational Modifications and Interaction Partners of Epidermal Growth Factor Receptor Signaling after Stimulation by Epidermal Growth Factor Using Extended Range Proteomic Analysis (ERPA)*S , 2006, Molecular & Cellular Proteomics.

[4]  Melissa A. Sandahl,et al.  The intracellular domain of ErbB4 induces differentiation of mammary epithelial cells. , 2006, Molecular biology of the cell.

[5]  Arvind K Pandey,et al.  Coregulation of estrogen receptor by ERBB4/HER4 establishes a growth-promoting autocrine signal in breast tumor cells. , 2006, Cancer research.

[6]  M. Hung,et al.  Nuclear‐cytoplasmic transport of EGFR involves receptor endocytosis, importin β1 and CRM1 , 2006, Journal of cellular biochemistry.

[7]  Makoto Ohnishi,et al.  ErbB2 receptor tyrosine kinase signaling mediates early demyelination induced by leprosy bacilli , 2006, Nature Medicine.

[8]  J. Baselga,et al.  Biosynthesis of tumorigenic HER2 C‐terminal fragments by alternative initiation of translation , 2006, The EMBO journal.

[9]  Carlos L Arteaga,et al.  HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. , 2006, Cancer cell.

[10]  Karin E. Borgmann-Winter,et al.  Altered neuregulin 1–erbB4 signaling contributes to NMDA> receptor hypofunction in schizophrenia , 2006, Nature Medicine.

[11]  J. Bartlett,et al.  The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells. , 2006, Cancer research.

[12]  P. Jänne,et al.  The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. , 2006, Cancer cell.

[13]  John Kuriyan,et al.  An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor Receptor , 2006, Cell.

[14]  H. Varmus,et al.  Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. , 2006, Genes & development.

[15]  B. H. Shah,et al.  TACE-dependent EGF receptor activation in angiotensin-II-induced kidney disease. , 2006, Trends in pharmacological sciences.

[16]  T. Hazlett,et al.  Structure and dynamics of the epidermal growth factor receptor C‐terminal phosphorylation domain , 2006, Protein science : a publication of the Protein Society.

[17]  Rüdiger Klein,et al.  Mig6 is a negative regulator of EGF receptor–mediated skin morphogenesis and tumor formation , 2006, Nature Medicine.

[18]  Paul J. Harrison,et al.  Neuregulin 1 transcripts are differentially expressed in schizophrenia and regulated by 5' SNPs associated with the disease. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Xuejun Jiang,et al.  Differential regulation of EGF receptor internalization and degradation by multiubiquitination within the kinase domain. , 2006, Molecular cell.

[20]  M. Hung,et al.  Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival , 2006, British Journal of Cancer.

[21]  J. Garcia-conde,et al.  p95HER-2 Predicts Worse Outcome in Patients with HER-2-Positive Breast Cancer , 2006, Clinical Cancer Research.

[22]  G. Carpenter,et al.  The ErbB-4 s80 intracellular domain is a constitutively active tyrosine kinase , 2006, Oncogene.

[23]  Ahmed Rebai,et al.  Electrostatic interactions of peptides flanking the tyrosine kinase domain in the epidermal growth factor receptor provides a model for intracellular dimerization and autophosphorylation , 2005, Proteins.

[24]  M. Hung,et al.  Endosomal Transport of ErbB-2: Mechanism for Nuclear Entry of the Cell Surface Receptor , 2005, Molecular and Cellular Biology.

[25]  D. Murray,et al.  Plasma membrane phosphoinositide organization by protein electrostatics , 2005, Nature.

[26]  John G Koland,et al.  Conformational changes accompany phosphorylation of the epidermal growth factor receptor C‐terminal domain , 2005, Protein science : a publication of the Protein Society.

[27]  Jorma Isola,et al.  Proteolytic cleavage and phosphorylation of a tumor-associated ErbB4 isoform promote ligand-independent survival and cancer cell growth. , 2005, Molecular biology of the cell.

[28]  Samuel Bouyain,et al.  The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[29]  G. Carpenter,et al.  Secretase-dependent Tyrosine Phosphorylation of Mdm2 by the ErbB-4 Intracellular Domain Fragment* , 2005, Journal of Biological Chemistry.

[30]  D. Lauffenburger,et al.  Time-resolved Mass Spectrometry of Tyrosine Phosphorylation Sites in the Epidermal Growth Factor Receptor Signaling Network Reveals Dynamic Modules*S , 2005, Molecular & Cellular Proteomics.

[31]  J. Schlessinger,et al.  Epidermal Growth Factor Receptor Dimerization and Activation Require Ligand-Induced Conformational Changes in the Dimer Interface , 2005, Molecular and Cellular Biology.

[32]  M. Conti,et al.  G-protein-coupled receptor signaling and the EGF network in endocrine systems , 2005, Trends in Endocrinology & Metabolism.

[33]  Edouard C. Nice,et al.  Ligand-induced Dimer-Tetramer Transition during the Activation of the Cell Surface Epidermal Growth Factor Receptor-A Multidimensional Microscopy Analysis* , 2005, Journal of Biological Chemistry.

[34]  O. Segatto,et al.  Targeted expression of RALT in mouse skin inhibits epidermal growth factor receptor signalling and generates a Waved‐like phenotype , 2005, EMBO reports.

[35]  Y. Pekarsky,et al.  WW domain-containing proteins, WWOX and YAP, compete for interaction with ErbB-4 and modulate its transcriptional function. , 2005, Cancer research.

[36]  L. Silengo,et al.  Systematic Analysis of the Epidermal Growth Factor Receptor by Mass Spectrometry Reveals Stimulation-dependent Multisite Phosphorylation*S , 2005, Molecular & Cellular Proteomics.

[37]  Shunqiang Li,et al.  Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach , 2005, Nature Medicine.

[38]  Chen Huiping,et al.  Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin , 2005, Oncogene.

[39]  Sheng-Chieh Hsu,et al.  Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. , 2005, Cancer cell.

[40]  M. Mann,et al.  Phosphotyrosine interactome of the ErbB-receptor kinase family , 2005, Molecular systems biology.

[41]  L. Marrero,et al.  Presenilin-dependent γ-Secretase Processing Regulates Multiple ERBB4/HER4 Activities* , 2005, Journal of Biological Chemistry.

[42]  C. Mermel,et al.  ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[43]  Sarel J Fleishman,et al.  A putative mechanism for downregulation of the catalytic activity of the EGF receptor via direct contact between its kinase and C-terminal domains. , 2004, Structure.

[44]  Frank E. Jones,et al.  The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by functioning as a STAT5A nuclear chaperone , 2004, The Journal of cell biology.

[45]  Joachim Herz,et al.  Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers? , 2004, Trends in molecular medicine.

[46]  M. Mann,et al.  Temporal analysis of phosphotyrosine-dependent signaling networks by quantitative proteomics , 2004, Nature Biotechnology.

[47]  L. Pelkmans,et al.  Not just a sink: endosomes in control of signal transduction. , 2004, Current opinion in cell biology.

[48]  B. H. Shah,et al.  Matrix metalloproteinase-dependent EGF receptor activation in hypertension and left ventricular hypertrophy , 2004, Trends in Endocrinology & Metabolism.

[49]  Stevan R. Hubbard,et al.  Juxtamembrane autoinhibition in receptor tyrosine kinases , 2004, Nature Reviews Molecular Cell Biology.

[50]  J. Buxbaum,et al.  Neuregulin 1-erbB signaling and the molecular/cellular basis of schizophrenia , 2004, Nature Neuroscience.

[51]  Nathan E Hall,et al.  CR1/CR2 Interactions Modulate the Functions of the Cell Surface Epidermal Growth Factor Receptor* , 2004, Journal of Biological Chemistry.

[52]  L. Frati,et al.  Ligand-regulated association of ErbB-4 to the transcriptional co-activator YAP65 controls transcription at the nuclear level. , 2004, Experimental cell research.

[53]  Peter Klein,et al.  The tethered configuration of the EGF receptor extracellular domain exerts only a limited control of receptor function. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[54]  K. Carraway,et al.  Negative regulation of ErbB family receptor tyrosine kinases , 2004, British Journal of Cancer.

[55]  Carlos Fernandez-Patron,et al.  Agonist-Induced Activation of Matrix Metalloproteinase-7 Promotes Vasoconstriction Through the Epidermal Growth Factor–Receptor Pathway , 2004, Circulation research.

[56]  M. Gassmann,et al.  ErbB4 Signaling During Breast and Neural Development: Novel Genetic Models Reveal Unique ErbB4 Activities , 2003, Cell cycle.

[57]  Richard S. Johnson,et al.  Studies of ligand-induced site-specific phosphorylation of epidermal growth factor receptor , 2003, Journal of the American Society for Mass Spectrometry.

[58]  N. Navin,et al.  WW Domain-containing Protein YAP Associates with ErbB-4 and Acts as a Co-transcriptional Activator for the Carboxyl-terminal Fragment of ErbB-4 That Translocates to the Nucleus* , 2003, Journal of Biological Chemistry.

[59]  S. Huong,et al.  Epidermal growth factor receptor is a cellular receptor for human cytomegalovirus , 2003, Nature.

[60]  G. Carpenter.  Nuclear localization and possible functions of receptor tyrosine kinases. , 2003, Current opinion in cell biology.

[61]  Michael Kofler,et al.  The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. , 2003, Molecular cell.

[62]  Hyun-soo Cho,et al.  EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. , 2003, Molecular cell.

[63]  H. Stefánsson,et al.  Neuregulin 1 and susceptibility to schizophrenia. , 2002, American journal of human genetics.

[64]  Jae-Hoon Kim,et al.  Crystal Structure of the Complex of Human Epidermal Growth Factor and Receptor Extracellular Domains , 2002, Cell.

[65]  Edouard C. Nice,et al.  Crystal Structure of a Truncated Epidermal Growth Factor Receptor Extracellular Domain Bound to Transforming Growth Factor α , 2002, Cell.

[66]  Hyun-soo Cho,et al.  Structure of the Extracellular Region of HER3 Reveals an Interdomain Tether , 2002, Science.

[67]  Mark von Zastrow,et al.  Signal transduction and endocytosis: close encounters of many kinds , 2002, Nature Reviews Molecular Cell Biology.

[68]  T. Golde,et al.  γ-Secretase Cleavage and Nuclear Localization of ErbB-4 Receptor Tyrosine Kinase , 2001, Science.

[69]  J. Baselga.  Is circulating HER-2 more than just a tumor marker? , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[70]  Y. Yarden,et al.  Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[71]  M. Crescenzi,et al.  Inhibition of ErbB-2 Mitogenic and Transforming Activity by RALT, a Mitogen-Induced Signal Transducer Which Binds to the ErbB-2 Kinase Domain , 2000, Molecular and Cellular Biology.

[72]  R. Gerlai,et al.  Heregulin, but not ErbB2 or ErbB3, heterozygous mutant mice exhibit hyperactivity in multiple behavioral tasks , 2000, Behavioural Brain Research.

[73]  J. Adelman,et al.  The HER-2/neu receptor tyrosine kinase gene encodes a secreted autoinhibitor. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[74]  J. Doherty,et al.  NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer. , 1998, Cancer research.

[75]  G. Scott,et al.  A truncated intracellular HER2/neu receptor produced by alternative RNA processing affects growth of human carcinoma cells , 1993, Molecular and cellular biology.

[76]  O. Hermanson,et al.  A basic peptide within the juxtamembrane region is required for EGF receptor dimerization. , 2005, Experimental cell research.

[77]  E. Neuwelt,et al.  Herstatin, an autoinhibitor of the epidermal growth factor receptor family, blocks the intracranial growth of glioblastoma. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[78]  Antony W Burgess,et al.  Epidermal growth factor receptor: mechanisms of activation and signalling. , 2003, Experimental cell research.

[79]  Mclaughlin.  Online Supplemental Material For , 2022 .